Axatilimab
Generic name: axatilimab
Brand name: Niktimvo
Dosage form: intravenous solution (csfr 22 mg/0.44 mL; csfr 9 mg/0.18 mL)
Drug class: Miscellaneous antineoplastics
What is axatilimab?
Axatilimab is used to treat chronic graft-versus-host disease in adults and children weighing at least 88.2 pounds (40 kg) who have received at least two prior treatments for this condition.
Axatilimab is given after other treatments did not work or stopped working.
Axatilimab may also be used for purposes not listed in this medication guide.
Axatilimab side effects
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Some side effects may occur during the infusion. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.
Common side effects of axatilimab may include:
-
viral or bacterial infections, fever;
-
muscle, bone, or joint pain;
-
lack of energy, headache;
-
abnormal blood tests;
-
cough; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Related/similar drugs
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Jakafi
Jakafi (ruxolitinib) is used to treat myelofibrosis, polycythemia vera, and graft versus host ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Trexall
Trexall is used for acute lymphoblastic leukemia, acute lymphocytic leukemia, breast cancer ...
Ruxolitinib
Ruxolitinib systemic is used for graft versus host disease, myelofibrosis, myeloproliferative ...
Ibrutinib
Ibrutinib (Imbruvica) is a Bruton's tyrosine kinase inhibitor used for certain blood cancers and ...
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Warnings
Axatilimab is given only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.
Before taking this medicine
Tell your doctor if you have or have ever had:
May harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use effective birth control while receiving axatilimab and for at least 30 days after your last dose. Tell your doctor if you become pregnant.
Do not breastfeed while receiving axatilimab, and for at least 30 days after your last dose.
How is axatilimab given?
Axatilimab is given as an infusion into a vein over 30 minutes. A healthcare provider will give you this infusion.
Axatilimab is usually given every 2 weeks. Your doctor will determine how long you should receive this medicine.
You will be watched for a short time to make sure you do not have an allergic reaction or serious side effects.
Your treatments may be delayed or stopped if you have certain side effects.
Doses are based on weight. Your dose may change if you gain or lose weight.
You will need frequent blood tests to check your liver function.
You may be given other medications to help prevent serious side effects or allergic reaction. Keep taking these medicines for as long as your doctor has prescribed.
Axatilimab dosing information
Usual Adult Dose for Graft Versus Host Disease:
Weight at least 40 kg: 0.3 mg/kg IV every 2 weeks
Maximum dose: 35 mg
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
-Infuse over 30 minutes.
-The manufacturer product information should be consulted for infusion rates.
Use: For the treatment of chronic graft-versus-host disease after failure of at least 2 prior lines of systemic therapy
Usual Pediatric Dose for Graft Versus Host Disease:
Weight at least 40 kg: 0.3 mg/kg IV every 2 weeks
Maximum dose: 35 mg
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
-Infuse over 30 minutes.
-The manufacturer product information should be consulted for infusion rates.
Use: For the treatment of chronic graft-versus-host disease after failure of at least 2 prior lines of systemic therapy
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your axatilimab infusion.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while receiving axatilimab?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
What other drugs will affect axatilimab?
Other drugs may affect axatilimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Axatilimab Biosimilars
Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.
Reference products
These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for axatilimab.
Niktimvo (axatilimab-csfr) - Incyte Corporation
Formulation type | Strength |
---|---|
Single-Dose Vial | 50 mg/mL |
View Niktimvo information in detail.
More about axatilimab
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2025 Cerner Multum, Inc. Version: 1.01.